The Ministry of Health has approved a trial of a gene therapy drug for hemophilia B. The trial is expected to be completed in mid-2031. The fact was stated in a publication in the state Register of medicines on February 20.
According to the Register, Phase I/II clinical trial is planned. It will study the safety and efficacy of the drug administered with a single intravenous injection, in incremental doses,
with the involvement of 54 participants. The trials are planned to be carried out in 13 medical centers located in Moscow, St. Petersburg, Ufa, Nizhny Novgorod, Samara, Chelyabinsk, Kemerovo, Novosibirsk, Syktyvkar, Kirov, and other cities.
At the end of 2022, it became known that Biocad is increasing the number of clinical trials of drugs for cancer, autoimmune and orphan diseases. Since 2020, the company has doubled the number of trials conducted.
